ZYHCG 2000 iu (ex.Ovidac)

Manufacturer: Cadila, India

Pharmaceutical name: Human Chorionic Gonadotropin

Pack: 1 set (vial 2000 iu + solution)

HCG is a hormone that is naturally generated by the female placenta during a normal pregnancy. The mechanism of this medication closely resembles that of luteinizing hormone (LH), which is recognized for its role in triggering ovulation. When used in combination with other medications, ZYHCG 2000 iu is particularly effective in assisting female patients in achieving pregnancy. This medication can also aid male patients experiencing fertility complications by often leading to increased testosterone production.

 

ZYHCG 2000 iu is widely prescribed to female patients as part of a treatment plan aimed at: inducing ovulation in cases of subfertility caused by impaired follicle development or anovulation; providing luteal phase support; and preparing follicles for puncture in controlled ovarian hyperstimulation programs, typically associated with medically assisted reproductive techniques.

 

ZYHCG is frequently prescribed to male patients due to its effectiveness in treating hypogonadotrophic hypogonadism. Some individuals with idiopathic dysspermias have responded favorably to treatment with this medication. It is also used for addressing delayed puberty linked to inadequate functioning of the gonadotrophic pituitary glands and cryptorchidism (excluding cases caused by anatomical obstructions).

 

ZYHCG is a well-regarded medication that supports both male and female patients in overcoming infertility. Additionally, it may serve other medical purposes not detailed in this text.

 

Female patients seeking treatment with ZYHCG should be aware that those undergoing assisted reproductive techniques, particularly in vitro fertilization, often face tubal abnormalities. Consequently, following treatment with this drug, there is a heightened risk of ectopic pregnancies, making early ultrasound confirmation essential to determine if the pregnancy is intrauterine. Pregnancies resulting from this medication may have an increased likelihood of multiple gestations. Women with a history of thrombosis, severe obesity, or thrombophilia should avoid this medication, as they are at greater risk for arterial or venous thromboembolic events during or after HCG treatment. Additionally, female patients who have undergone treatment with this medication may be more susceptible to pregnancy loss.

 

In the context of male patients: Long-term use of ZYHMG HCG is known to frequently lead to heightened androgen production. Therefore, individuals with overt or latent cardiac failure, hypertension, renal dysfunction, migraines, or epilepsy may need to be cautious when using this medication and may require a lower dosage of ZYHCG 2000 iu. This medication should be administered with great care to prepubescent teenagers to mitigate the risk of precocious sexual development or premature epiphyseal closure, necessitating close monitoring of their skeletal maturation.

 

Both male and female patients with the following medical conditions should refrain from starting treatment with ZYHCG: hypersensitivity to this medication or any of its components, and known or suspected androgen-dependent tumors, such as male breast carcinoma or prostatic carcinoma.

 

Consult your physician regarding the correct usage and timing of this medication. It is crucial to adhere to your physician's guidance. Additional instructions can also be found on the drug label. For any further questions, please reach out to a doctor, pharmacist, or nurse. HCG should be refrigerated at a temperature between 2°-8°C, kept out of direct sunlight, and stored in a location inaccessible to pets and children to prevent accidental poisoning.

 

Recommended dosage for female patients: One injection of 5,000-10,000 I.U. of this medication. Recommended dosage for male patients: An injection of 1,000-2,000 I.U., administered 2 to 3 times each week. Ideally, each dose of HCG should be given by a qualified healthcare provider.

 

The acute toxicity of this medication is very low, and the typical symptoms of an overdose with ZYHCG in humans are not well-documented.

 

Prolonged treatment with this medication can lead to various reactions at the injection site, including pain, bruising, redness, itching, and swelling. Some patients treated with HCG have experienced allergic reactions, such as rash, pain, or swelling at the injection site. Rare side effects of ZYHCG may include fever or rash.

 

Female patients treated with this medication have reported experiencing ovarian hyperstimulation syndrome. Male patients who have received ZYHCG may occasionally experience sodium and water retention, particularly after being given high dosages of the medication, likely due to excessive androgen production. In some instances, treatment with ZYHCG could potentially result in gynecomastia.